Findings of multiple muscle involvement in a study of 214 patients with laryngeal dystonia using fine-wire electromyography

Annals of Otology, Rhinology and Laryngology

Volumn 113, Issue 8, 2004, Pages 602-612

  Klotz, Darrell A ^a,b   Shahinfar, Ariana ^a,b   Maronian, Nicole C ^a,b   Robinson, Lawrence ^a,c   Waugh, Patricia F ^a,b   Hillel, Allen D ^a,b,d  

^a University of Washington ^*

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Botulinum toxin; Electromyography; Fine wire electromyography; Laryngeal dystonia; Perceptual analysis; Spasmodic dysphonia; Tremor; Voice quality

Indexed keywords

BOTULINUM TOXIN;

ADDUCTOR SPASMODIC DYSPHONIA; ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRICOARYTENOID MUSCLE; DISEASE CLASSIFICATION; DYSPHONIA; ELECTROMYOGRAPHY; FINE WIRE ELECTROMYOGRAPHY; HUMAN; INTERMETHOD COMPARISON; LARYNGEAL DYSTONIA; LARYNX DISORDER; LARYNX MUSCLE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STROBOSCOPY; THYROARYTENOID MUSCLE; TREATMENT FAILURE; TREMOR; TREMOR SPASMODIC DYSPHONIA; VIDEOSTROBOSCOPY; VOCAL TREMOR; VOICE;

EID: 3543103263     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940411300802     Document Type: Article

References (58)

1. Blitzer A, Brin MF. Laryngeal dystonia: a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 1991;100: 85-9.
2. Blitzer A, Lovelace RE, Brin MF, Fahn S, Fink ME. Electromyographic findings in focal laryngeal dystonia (spastic dysphonia). Ann Otol Rhinol Laryngol 1985;94:591-4.
3. Ford CN. Laryngeal EMG in clinical neurolaryngology. Arch Otolaryngol Head Neck Surg 1998;124:476-7.
4. Blitzer A, Brin MF, Fahn S, Lovelace RE. Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope 1988;98:193-7.
5. Woodson GE, Zwirner P, Murry T, Swenson M. The use of flexible fiberoptic laryngoscopy to assess patients with spasmodic dysphonia. J Voice 1991;5:85-91.
6. Freeman FJ, Cannito MP, Finitzo-Hieber T. Classification of spasmodic dysphonia by perceptual-acoustic-visual means. In: Gates GA, ed. Spasmodic dysphonia: state of the art 1984. New York, NY: The Voice Foundation, 1985:5-15.
7. Koufman JA. Classification of laryngeal dystonias. In: Koufman JA, ed. The visible voice. Winston-Salem, NC: The Center for Voice Disorders of Wake Forest University, 1992;1:1-22.
8. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998; 108:1435-41.
9. Zwirner P, Murry T, Woodson GE. Perceptual-acoustic relationships in spasmodic dysphonia. J Voice 1993;7:165-71.
10. Blitzer A, Brin MF, Stewart C, Aviv JE, Fahn S. Abductor laryngeal dystonia: a series treated with botulinum toxin. Laryngoscope 1992;102:163-7.
11. Aronson A. Abductor spastic dysphonia. In: Aronson A, ed. Clinical voice disorders. New York, NY: Thieme Medical Publishing, 1985:187-97.
12. Ford CN, Bless DM, Lowery JD. Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia. Otolaryngol Head Neck Surg 1990;103:752-8.
13. Dedo HH, Izdebski K. Intermediate results of 306 recurrent laryngeal nerve sections for spastic dysphonia. Laryngoscope 1983;93:9-16.
14. Aronson AE, De Santo LW. Adductor spastic dysphonia: three years after recurrent nerve resection. Laryngoscope 1983; 93:1-8.
15. Zwirner P, Murry T, Swenson M, Woodson GE. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope 1992;102:400-6.
16. Ludlow CL. Treatment of speech and voice disorders with botulinum toxin. JAMA 1990;264:2671-5.
17. Ludlow CL, Hallet M, Sevory SE, Fujita M, Naunton R. The pathophysiology of spasmodic dysphonia and its modification by botulinum toxin. In: Berardelli A, Benecke R, eds. Motor disturbances II. London, England: Academic Press, 1990: 274-88.
18. Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991;101:630-4.
19. Courey MS, Garrett CG, Billante CR, et al. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. Ann Otol Rhinol Laryngol 2000;109:819-22.
20. Whurr R, Nye C, Lorch M. Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies. Int J Lang Commun Disord 1998;33(suppl):327-9.
21. American Academy of Otolaryngology-Head and Neck Surgery Policy Statement. Botox for spasmodic dysphonia. In: Bulletin: AAO-HNS Bulletin 1990;9:8.
22. National Institutes of Health Consensus Development Conference Consensus Statement. Clinical use of botulinum toxin. Nat Inst Health Consensus Dev Conf Consensus Statement 1990;8.
23. Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1990;40:1332-6.
24. Ludlow CL, Naunton RF, Sedory SE, Schulz GM, Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 1988;38:1220-5.
25. Ludlow CL, Naunton RF, Terada S, Anderson BJ. Successful treatment of selected cases of abductor spasmodic dysphonia using botulinum toxin injection. Otolaryngol Head Neck Surg 1991;104:849-55.
26. Inagi K, Ford CN, Bless DM, Heisey D. Analysis of factors affecting botulinum toxin results in spasmodic dysphonia. J Voice 1996;10:306-13.
27. Koda J, Ludlow CL. An evaluation of laryngeal muscle activation in patients with voice tremor. Otolaryngol Head Neck Surg 1992;107:684-96.
28. Hertegard S, Granqvist S, Lindestad PA. Botulinum toxin injections for essential voice tremor. Ann Otol Rhinol Laryngol 2000;109:204-9.
29. Warrick P, Dromey C, Irish J, Durkin L. The treatment of essential voice tremor with botulinum toxin A: a longitudinal case report. J Voice 2000;14:410-21.
30. Warrick P, Dromey C, Irish JC, Durkin L, Pakiam A, Lang A. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. Laryngoscope 2000;110:1366-74.
31. Hillel AD. The study of laryngeal muscle activity in normal human subjects and in patients with laryngeal dystonia using multiple fine-wire electromyography. Laryngoscope 2001; 111(suppl 97).
32. Rodriquez AA, Myers BR, Ford CN. Laryngeal electromyography in the diagnosis of laryngeal nerve injuries. Arch Phys Med Rehabil 1990;71:587-90.
33. Parnes SM, Saty-Murti S, Crane S. Laryngeal electromyography. Clinical application. N Y State J Med 1983;83:329-33.
34. Dray TG, Robinson LR, Hillel AD. Idiopathic bilateral vocal fold weakness. Laryngoscope 1999;109:995-1002.
35. Koufman JA, Walker FO. Laryngeal electromyography in clinical practice: indications, techniques and interpretations. Phonoscope 1998;1:57-70.
36. Koufman JA, Postma GN, Whang CS, et al. Diagnostic laryngeal electromyography: the Wake Forest experience 1995-1999. Otolaryngol Head Neck Surg 2001;124:603-6.
37. Hillel AD, Benninger M, Blitzer A, et al. Evaluation and management of bilateral vocal cord immobility. Otolaryngol Head Neck Surg 1999;121:760-5.
38. Blair RL, Berry H, Briant TD. Laryngeal electromyography: techniques and application. Otolaryngol Clin North Am 1978;11:325-46.
39. Hirose H. Electromyography of the larynx and other speech organs. In: Sawashima M, ed. Dynamic aspects of speech production. Tokyo, Japan: Tokyo Press, 1977:49-67.
40. Fritzell B, Feuer E, Haglund S, Knutsson E, Schiratzki H. Experiences with recurrent laryngeal nerve section for spastic dysphonia. Folia Phoniatr (Basel) 1982;34:160-7.
41. Rodriquez AA, Ford CN, Bless DM, Harmon RL. Electromyographic assessment of spasmodic dysphonia patients prior to botulinum toxin injection. Electromyogr Clin Neurophysiol 1994;34:403-7.
42. Schaefer S, Watson B, Freeman F, et al. Vocal tract electromyographic abnormalities in spasmodic dysphonia. Preliminary report. Trans Am Laryngol Assoc 1987;108:187-96.
43. Schaefer SD, Roark RM, Watson BC, et al. Multichannel electromyographic observations in spasmodic dysphonia patients and normal control subjects. Ann Otol Rhinol Laryngol 1992;101:67-75.
44. Shipp T, Izdebski K, Reed C, Morrissey P. Intrinsic laryngeal muscle activity in a spastic dysphonia patient. J Speech Hear Disord 1985;50:54-9.
45. Van Pelt F, Ludlow CL, Smith PJ. Comparison of muscle activation patterns in adductor and abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 1994;103:192-200.
46. Bielamowicz S, Squire S, Bidus K, Ludlow CL. Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 2001;110:406-12.
47. Nash EA, Ludlow CL. Laryngeal muscle activity during speech breaks in adductor spasmodic dysphonia. Laryngoscope 1996;106:484-9.
48. Cyrus CB, Bielamowicz S, Evans FJ, Ludlow CL. Adductor muscle activity abnormalities in abductor spasmodic dysphonia. Otolaryngol Head Neck Surg 2001;124:23-30.
49. Hirano M, Ohala J. Use of hooked-wire electrodes for electromyography of the intrinsic laryngeal muscles. J Speech Hear Res 1969;12:363-73.
50. Murry T, Cannito MP, Woodson GE. Spasmodic dysphonia. Emotional status and botulinum toxin treatment. Arch Otolaryngol Head Neck Surg 1994;120:310-6.
51. Langeveld TP, Luteijn F, van Rossum M, Drost HA, de Jong RJ. Adductor spasmodic dysphonia and botulinum toxin treatment: the effect on well-being. Ann Otol Rhinol Laryngol 2001;110:941-5.
52. Murry T, Woodson GE. Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy. J Voice 1995;9:460-5.
53. Langeveld TP, van Rossum M, Houtman EH, Zwinderman AH, Briaire JJ, Baatenburg de Jong RJ. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment. Ann Otol Rhinol Laryngol 2001;110:627-34.
54. Whurr R, Lorch M, Fontana H, Brookes G, Lees A, Marsden CD. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. J Neurol Neurosurg Psychiatry 1993; 56:526-30.
55. Mehta RP, Goldman SN, Orloff LA. Long-term therapy for spasmodic dysphonia: acoustic and aerodynamic outcomes. Arch Otolaryngol Head Neck Surg 2001;127:393-9.
56. Parnes SM, Lavorato AS, Myers EN. Study of spastic dysphonia using videofiberoptic laryngoscopy. Ann Otol Rhinol Laryngol 1978;87:322-6.
57. McCall GN, Skolnick ML, Brewer DW. A preliminary report of some atypical movement patterns in the tongue, palate, hypopharynx, and larynx of patients with spasmodic dysphonia. J Speech Hear Disord 1971;36:466-75.
58. Hillel AD, Maronian NC, Waugh PF, Robinson L, Klotz DA. Treatment of the interarytenoid muscle with botulinum toxin for laryngeal dystonia. Ann Otol Rhinol Laryngol 2004;113: 341-8.